Information

2013/02/28

Patent established additional usage in Japan of F647 and F351 to cover application for Preventing Radiation-Caused Lung Injury in Japan, also in the U.S. obtained patent for pharmaceutical composition of F200

2013/02/14

Announcement of the 12th Annual General Shareholder Meeting

2013/02/04

Submission of Manufacturing and Distribution Permission Application regarding IPF treatment drug, F647

2013/01/23

GNI Seeks New Indication for F647 (Pirfenidone)

2013/01/16

Notice of Increasing the Capital of Shanghai Genomics

2012/11/29

The Beijing Evening News channel visited Beijing Continent Pharmaceuticals for its pirfenidone product development program and interviewed Dr. Ying Luo.

2012/10/30

G20 Innovation Award

2012/10/17

F351 clinical trial for liver fibrosis

2012/06/18

BIO2012

2012/06/12

Patent Allowance for Pirfenidone／F647 and its Derivative’s Use in Radiation-Caused Lung Injury